Phenothiazines (including Hydrogenated) Patents (Class 514/224.8)
-
Publication number: 20130243858Abstract: Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods.Type: ApplicationFiled: November 30, 2011Publication date: September 19, 2013Inventor: Karrar Ahmad Khan
-
Publication number: 20130210807Abstract: The present invention describes and claims compounds of the Structural Formula I, Structural Formula II, or Structural Formula III: wherein R1, R2, R3 and R3? are —H or methyl, or R3 and R3 taken together form a double bond, or R3? is —H and R2 and R3 taken together form a spiro-cyclopropyl substituent, R4 is —H or —F, and R5 is —H, methyl, —CI or —Br, Formula II wherein R1 is —H, ethyl-, isopropyl-, cyclopropyl-, methyl- or methoxy-, R4 is —H or —F, and “Y” is: (a) —CH2—; (b) —CR6H-0-CR7R8—, wherein R6, R7, and R8 are independently —H or methyl; (c) —CR6H—N(R9)—CR7R8—, wherein R6, R7, and R8 are independently —H or methyl; (d) —CH2—C(R9)(R10)—C(R7)(R8)—, wherein R7, R8, R9 and R10 are independently —H or -methyl, or both R7 and R8 are —F, R9 and R10 are independently —H or -methyl, or both R9 and R10 are —F, or R9 and R10 taken together are (0=), which together with the carbon to which they are attached forms a carbonyl group.Type: ApplicationFiled: July 9, 2011Publication date: August 15, 2013Inventors: Nigel J Liverton, Christelle Boléa, Sylvain Celanire, Yunfu Luo
-
Publication number: 20130184267Abstract: In one aspect, compositions provide antimicrobial therapy as topical disinfectants. Particularly, one aspect relates to an alcohol containing antimicrobial composition that includes at least one paraben, a redox compound and an organic acid at a concentration of from about 1.5 percent to about 10 percent by weight, based on the total weight of the composition. In other aspects, antimicrobial compositions are used to topically sanitize wounds, skin areas and/or to disinfect surgical instruments or other surfaces. Still, in further aspects, methods, devices and kits relating to an antimicrobial composition are provided.Type: ApplicationFiled: March 4, 2013Publication date: July 18, 2013Applicant: ZUREX PHARMA, INC.Inventor: ZUREX PHARMA, INC.
-
Publication number: 20130178466Abstract: The invention provides compositions, medicaments and methods of treating microbial infections, and especially respiratory disorders caused by microbial infections. In particular, the invention relates to the treatment of respiratory diseases caused by pathogenic infections using certain either alkyl substituted or un-substituted 2-aryl acetic acid, or 2-aryl, N-hydroxyacetamide derivatives, or pentoxifylline, and to the use of these compounds in methods of treatment.Type: ApplicationFiled: November 9, 2010Publication date: July 11, 2013Applicant: BIOCOPEA LIMITEDInventors: Robin Mark Bannister, Wilson Caparros Wanderlay, John Brew
-
Publication number: 20130115133Abstract: The present invention relates the use of phenothiaziniums and microbial MDR inhibitors to inactivate microorganisms. Methods of the present invention are useful in the treatment of living subjects and in the decontamination of inanimate objects and substances.Type: ApplicationFiled: June 19, 2012Publication date: May 9, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Michael R. Hamblin, George P. Tegos
-
Publication number: 20130085137Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.Type: ApplicationFiled: September 21, 2012Publication date: April 4, 2013Applicant: Hydromer, Inc.Inventor: Hydromer, Inc.
-
Publication number: 20130045253Abstract: Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product.Type: ApplicationFiled: October 17, 2012Publication date: February 21, 2013Inventors: Andrew Chen, Hailiang Chen, James Cecil Free, Majid Keshtmand, Mohammed Abdul Rahman, Sally Look
-
Publication number: 20130035284Abstract: The present invention concerns methods and compositions involving small molecule inhibitors for the treatment or prophylaxis of flavivirus infection, such as dengue virus and West Nile virus.Type: ApplicationFiled: March 5, 2012Publication date: February 7, 2013Applicant: The Board of Regents of the University of Texas SystemInventors: Stanley J. Watowich, Suzanne M. Tomlinson, Scott Gilbertson
-
Publication number: 20130005713Abstract: Process for preparing compounds of the diaminophenothiazinium type including a step for purification of derivatives (II). The products resulting from this process have a high degree of purity. Use of these compounds for the preparation of medicaments.Type: ApplicationFiled: July 19, 2012Publication date: January 3, 2013Applicant: PROVENCE TECHNOLOGIESInventors: Michel Feraud, Babak Sayah
-
Publication number: 20120328530Abstract: A compound of formula (III), or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen and/or tumour cells; wherein X is selected from O, S and Se; each of R2, R3 and R4 is independently selected from hydrogen or an optionally substituted alkyl, alkenyl, alkynyl or aryl group; and R1 is selected from halogen, sulfo, acyl, sulfoxy, mercapto, nitro, amino, hydroxy or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; wherein R1 is not methyl or hydrogen when each of R3 and R4 is methyl or hydrogen.Type: ApplicationFiled: March 11, 2011Publication date: December 27, 2012Applicant: PHARMALUCIA LIMITEDInventor: Mark Wainwright
-
Publication number: 20120302556Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: ApplicationFiled: March 29, 2012Publication date: November 29, 2012Applicant: PROSETTA ANTIVIRAL INC.Inventors: Clarence R. Hurt, Vishwanath Lingappa, Beverly Freeman, Andy Atuegbu, Anatoliy Kitaygorodskyy
-
Publication number: 20120289499Abstract: Substantially pure methylthioninium chloride pentahydrate form A is prepared from methylthioninium chloride by phase equilibration of suspensions, crystallization or solvent evaporation, whereby the water content of the solvent corresponds to a water activity of at least 0.4 at 25° C., and controlled drying of said methylthioninium chloride pentahydrate form A within its stability ranges of humidity, pressure and temperature.Type: ApplicationFiled: September 23, 2010Publication date: November 15, 2012Inventors: Rolf Hilfiker, Timo Rager
-
Patent number: 8278298Abstract: A composition and use thereof for the prophylaxis or treatment of Alzheimer's disease, motor neurone disease, Lewy body disease, Pick's disease or progressive supranuclear palsy. The composition includes an agent which modulates or inhibits tau-tau association and which does not inhibit tau-tubulin binding. In the method the agent is administered to an individual in order to achieve the desired therapeutic effect. Preferably the agent which is administered is a phenothiazine compound.Type: GrantFiled: December 11, 2006Date of Patent: October 2, 2012Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, Patricia Carol Edwards, Charles Robert Harrington, Martin Roth, Aaron Klug
-
Publication number: 20120238556Abstract: Three dihydrate forms B, C and D and a monohydrate form E of methylthioninium chloride are described. Forms B, C, D and E can be prepared under controlled humidity and temperature from methylthioninium chloride with higher water content or conversion of a hydrate. The hydrates can be incorporated in pharmaceutical compositions.Type: ApplicationFiled: September 23, 2010Publication date: September 20, 2012Inventors: Rolf Hilfiker, Timo Rager
-
Publication number: 20120238543Abstract: Novel compounds, methods, and compositions for treating various viral infections are described. In some embodiments the novel compounds of the invention are 3-oxo-phenothiazine derivatives; more specific embodiments include 3-oxo-phenothiazine derivatives having substituents at the 1-, 7-, and 9-positions of the phenothiazine parent ring. In other embodiments, the invention provides compositions and methods for treating viral infections, especially HIV.Type: ApplicationFiled: March 16, 2012Publication date: September 20, 2012Applicant: Prosetta Antiviral, Inc.Inventors: Clarence Hurt, Beverly Freeman, Vishwanath Lingappa, Andy Atuegbu, Anatoliy Kitaygorodskyy
-
Patent number: 8263589Abstract: The invention relates generally to the use of diaminophenothiazine compounds to inhibit or reverse the aggregation of synuclein, and for their use in the manufacture of medicaments for this purpose (e.g. for the treatment of Parkinson's Disease). Also provided are related methods of detecting or labelling of aggregated synuclein.Type: GrantFiled: March 28, 2007Date of Patent: September 11, 2012Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, Janet Elizabeth Rickard, Charles Robert Harrington, David Horsley
-
Patent number: 8247406Abstract: The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and less than about 2% v/v, and a pharmaceutically acceptable carrier to a treatment site; and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to reduce the microbes at the treatment site.Type: GrantFiled: July 30, 2009Date of Patent: August 21, 2012Assignee: Ondine International Ltd.Inventors: Cale Street, Nicolas Loebel, Lisa Pedigo
-
Publication number: 20120189710Abstract: Compositions and their use for treating bacterial infections are described, in particular compositions for treating multi-species infections and the treatment of bacterial infections arising from biofilms. The present invention also relates to antibacterial compositions for treating dental diseases. Compositions of the present invention may include a garlic extract or S-allyl cysteine, and optionally an antibiotic and/or an antiseptic.Type: ApplicationFiled: July 28, 2010Publication date: July 26, 2012Inventor: Raymond S. Steggles
-
Patent number: 8227459Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: GrantFiled: April 3, 2008Date of Patent: July 24, 2012Assignee: Prosetta Antiviral Inc.Inventors: Jacob Plattner, Colm Kelleher, Vishwanath Lingappa, Beverly Freeman, William Hansen
-
Publication number: 20120157435Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and respiratory viruses including the common cold.Type: ApplicationFiled: May 2, 2011Publication date: June 21, 2012Applicant: PROSETTA ANTIVIRAL INC.Inventors: Clarence Hurt, Beverly Freeman, Vishwanath Lingappa, Andy Atuegbu, Anatoliy Kitaygorodorskyy
-
Publication number: 20120148604Abstract: The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.Type: ApplicationFiled: August 20, 2010Publication date: June 14, 2012Applicant: TRANSPOSAGEN BIOPHARMACEUTICALS, INC.Inventors: Eric M. Ostertag, John Stuart Crawford
-
Patent number: 8188074Abstract: The present invention relates to a composition which includes a moiety of formula wherein R1, R2, R3 and R4 each represent n-pentyl, and to a method of sterilizing a su fluid using same.Type: GrantFiled: May 12, 2008Date of Patent: May 29, 2012Assignee: Photopharmica LimitedInventors: Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, David Ian Vernon
-
Publication number: 20120121723Abstract: An antimicrobial composition, including a synergistic combination of three or more agents as an active ingredient. Each of the three or more potentiating agents can be selected from the following types of compounds: sequestering agents, carbohydrates and carbohydrate derivatives, terpenes/terpenoids, amines and amine derivatives, plant-derived oils, sulfonates, phenols, fatty acids, dibenzofuran derivatives, organo isothiocyanates, quaternary ammonium compounds, peroxides and peroxide donors, and macrolide polyenes. At least two of the three or more potentiating agents are not of the same type of compound. The antimicrobial composition can have strong antimicrobial efficacy in control of microorganisms having resistance to currently used antimicrobials.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: Sterilex Technologies, LLCInventors: Pradip Mookerjee, Shira Kramer, Alexander Josowitz, April Zambelli-Weiner
-
Publication number: 20120101089Abstract: The present invention provides a therapeutic solution for effective control of symptoms related to nausea and vomiting. The therapeutic solution is a pharmaceutical composition which combines anti-emetics of different classes. These classes include dopamine receptor antagonists, serotonin receptor antagonists, butyrphenones, and neurokinin receptor antagonists. The combination of different anti-emetics mitigates adverse affects of a single anti-emetic alone while increasing drug efficacy and decreasing cost of administration to the individual patient.Type: ApplicationFiled: June 8, 2011Publication date: April 26, 2012Inventors: Ashwani Agarwal, Ankit Bharat
-
Publication number: 20120094985Abstract: The invention relates to a pharmaceutical composition for treating serotonergic neurotransmission related disease or condition, including an effective amount of a chlorophenylpiperazine derived compound of Formula (I), or the pharmaceutically acceptable salt thereof. The pharmaceutical composition is safe and does not have side effect on lethargy.Type: ApplicationFiled: December 29, 2011Publication date: April 19, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventor: Ing-Jun Chen
-
Publication number: 20120058995Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the e//i method comprises the steps of in order: a thiosulfonic acid formation (TSAF) as illustrated below, wherein the reaction is carried out in the presence of a thio sulfate and an oxidizing agent that is or comprises persulfate an oxidative coupling (OC); and a ring closure (RC). The resulting compounds and compositions comprising them (e.g., tablets, capsules) are useful in methods of medical treatment and diagnosis, etc., for example, tauopathies, or Alzheimer's disease (AD).Type: ApplicationFiled: May 11, 2010Publication date: March 8, 2012Applicant: WisTa Laboratories Ltd.Inventors: Christopher Paul Larch, John Mervyn David Storey, Craig Williamson, Colin Marshall, Steven John Kemp
-
Publication number: 20120029418Abstract: The present invention includes a composition for photoablation comprising a photosensitizer and ethylenediaminetetraacetic acid (“EDTA”) at a very low concentration (e.g., ranging from about 0.01 mM to about 1.25 mM), wherein the composition is used for photoablation of at least one targeted organism. The present invention also includes a method for photoablation comprising applying the composition to a treatment site containing at least one targeted organism and applying light to the treatment site at a wavelength absorbed by the photosensitizer so as to inhibit the at least one targeted organism.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Inventor: Merrill Biel
-
Publication number: 20120015331Abstract: The present invention provides a polymeric scaffold containing an antibacterial photoactive drug and optionally comprising seeded cells such as stem cells. The invention also includes methods of using the scaffold for tissue regeneration, prevention or reduction of infection whilst tissue regeneration occurs, methods for improving graft or implant survival, promoting scaffold integration and tissue repair and wound healing.Type: ApplicationFiled: March 23, 2010Publication date: January 19, 2012Inventors: Simon Wood, Xuebin Yang, Marcel de Matas, Peter Iddon, Michael Raxworthy
-
Patent number: 8097615Abstract: Disclosed are in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.Type: GrantFiled: May 10, 2010Date of Patent: January 17, 2012Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, Charles Robert Harrington, Janet Elizabeth Rickard, David Horsley
-
Patent number: 8088762Abstract: The invention describes novel nitrosated nonsteroidal anti-inflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: GrantFiled: December 11, 2009Date of Patent: January 3, 2012Assignee: NiCox S.A.Inventors: Richard A. Earl, Maiko Ezawa, Xinqin Fang, David S. Garvey, Ricky D. Gaston, Subhash P. Khanapure, L. Gordon Letts, Chia-En Lin, Ramani R. Ranatunge, Stewart K. Richardson, Joseph D. Schroeder, Cheri A. Stevenson, Shiow-Jyi Wey
-
Publication number: 20110306576Abstract: A compound of formula (II) or a pharmaceutically acceptable derivative thereof for use in a method of combating and/or detecting a pathogen; wherein X is selected from O, S and Se; each of R1, R2, R4, R6, R8, R9, R11, R12, R13 and R14 is independently selected from hydrogen, halogen, sulfo, sulfoxy, mercapto, acyl, nitro, amino or an optionally substituted alkyl, alkenyl, alkynyl, aryl, amine or alkoxy group; provided that at least one of R11, R12, R13 and R14 is an optionally substituted amine group.Type: ApplicationFiled: February 25, 2010Publication date: December 15, 2011Applicant: PHARMALUCIA LIMITEDInventor: Mark Wainwright
-
Publication number: 20110301153Abstract: The invention concerns methods of treating cancer comprising contacting said tumors with a chemical inhibitor of glutaminolysis. These inhibitors include amino-oxyacetate, phenylbutyrate, phenylacetate, and 3,7-bis(dimethylamino)-phenazathionium chloride (methylene blue).Type: ApplicationFiled: November 16, 2009Publication date: December 8, 2011Applicant: The Trustees of the University of PennsylvaniaInventors: Craig B. Thompson, David R. Wise
-
Publication number: 20110301154Abstract: The present invention involves new and original sigma receptors Ligands: (Mono-or dialkylaminoalkyl)-?-butyro-lactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl ?-[(adamantyl-1)ben-zyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or di-astereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Astemizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, an-timetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotectve and cytoregenerative activity against the cytodegenerative diseases.Type: ApplicationFiled: February 17, 2010Publication date: December 8, 2011Inventor: Alexandre Vamvakides
-
Publication number: 20110257586Abstract: The present invention provides pharmaceutical photosensitizer-loaded nanoparticle formulations and their methods of preparation for photodynamic therapy, comprising a hydrophobic or hydrophilic photosensitizer, nanoparticulate calcium phosphate and in certain cases auxiliary reagents such as stabilizers. The calcium phosphate-based nanoparticle formulations of the present invention provide excellent storage stability and therapeutically effective amounts of photosensitizer for intravenous or topical administration. In a preferred embodiment, tetrapyrrole derivatives such as porphyrins, chlorins and bacteriochlorins, are the preferred hydrophobic photosensitizers to be formulated in calcium phosphate nanoparticle formulations for photodynamic tumor therapy. Additionally, 5,10,15,20-tetrakis(4-phosphonooxyphenyl)porphine (pTPPP) is a preferred hydrophilic photosensitizer for photodynamic tumor therapy.Type: ApplicationFiled: December 18, 2009Publication date: October 20, 2011Applicants: UNIVERSITAT DUISBURG-ESSEN, BIOLITEC AGInventors: Burkhatd Gitter, Susanna Grafe, Arno Wiehe, Volker Albrecht, Matthias Epple, Janine Schwiertz, Kathirvel Ganesan
-
Publication number: 20110250296Abstract: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.Type: ApplicationFiled: June 23, 2011Publication date: October 13, 2011Inventor: David E. Winslow
-
Publication number: 20110230474Abstract: The invention includes a method of treating a mammal comprising topically applying an aqueous composition to a target site on the mammal, wherein the aqueous composition comprises: active ingredients comprising i) a cosmetic dye selected from a violet, blue or green dye, or combinations thereof, and ii) an enhancing ingredient, wherein the relative weight percentage of the cosmetic dye to the enhancing ingredient is about 1:2 to about 40:1, wherein the cosmetic dye interacts with keratinous material thereby i) substantially staining the target site and ii) inhibiting the active ingredients from significantly leaching from the target site.Type: ApplicationFiled: January 14, 2011Publication date: September 22, 2011Inventors: Irina Grigorian, Manfred F. Dyck, Rainer Gruening
-
Publication number: 20110217202Abstract: The present invention provides a lens care kit for disinfecting and/or cleaning contact lenses. The lens care kit of the invention comprising: (1) a lens care solution; (2) a lens case for holding the lens care solution and a contact lens immersed in the lens care solution; (3) a singlet oxygen-generating agent which is dissolved or dispersed in a lens care solution; and (4) a light irradiation source for irradiating the singlet oxygen-generating agent for a period of time sufficient to produce a sufficient amount of singlet oxygen in the lens care solution to disinfect the contact lens.Type: ApplicationFiled: March 7, 2011Publication date: September 8, 2011Inventor: Lynn Cook Winterton
-
Publication number: 20110178071Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.Type: ApplicationFiled: April 3, 2008Publication date: July 21, 2011Inventors: Jacob Plattner, Colm Kelleher, Vishwanath Lingappa, Beverly Freeman, William Hansen
-
Patent number: 7968127Abstract: A formulation or preparation for treating and preventing arterial and venous thrombi is provided. This preparation includes a non-metal containing photodynamic dye and a fat soluble vitamin. A method of administration for treatment and prophylaxis of arterial and venous thrombi is also provided. This method includes steps of: combining a non-metal containing photodynamic dye and a fat soluble vitamin; combining the non-metal containing photodynamic dye and fat soluble vitamin with a sodium solution; and administering the combination of non-metal containing photodynamic dye, fat soluble vitamin, and sodium solution as an intravenous drip.Type: GrantFiled: July 28, 2008Date of Patent: June 28, 2011Inventor: David E. Winslow
-
Publication number: 20110152219Abstract: The use of enhancers with possibly riboflavin, as well as the corresponding compositions for the treatment of keratoconus or other ectasic corneal disorders by the method of corneal cross-linking.Type: ApplicationFiled: February 28, 2011Publication date: June 23, 2011Applicant: SOOFT ITALIA SPAInventors: Marcello STAGNI, Edoardo STAGNI, Massimo FILIPPELLO, Giovanni CAVALLO, Eugenio SODO
-
Publication number: 20110136790Abstract: The present invention relates to novel Tricyclic Heterocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Heterocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is formula (Ia), (Ib) or (Ic); R2 is alkvl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl. any of which can be optionally substituted with R11; M1 is —CH—. —C(halo)- or —N—; Y is —C(O)—, —S—. —S(O)—, —S(O)2—, —CH2— or —O—, such that Y is not —O— when an adjacent atom is N.Type: ApplicationFiled: July 21, 2009Publication date: June 9, 2011Inventors: Manuel De Lera Ruiz, MIchael Y Berlin, Junying Zheng, Robert G. Aslanian, Kenvin D. McCormick, Qingbel Zeng
-
Publication number: 20110130392Abstract: A method of administering a methylene blue-curcumin hybrid useful in treating or preventing Alzheimer's Disease.Type: ApplicationFiled: November 30, 2010Publication date: June 2, 2011Inventors: Thomas M. DiMauro, Sean Lilienfeld
-
Publication number: 20110117202Abstract: Methods and systems for producing a change in a medium. A first method and system (1) place in a vicinity of the medium at least one upconverter including a gas for plasma ignition, with the upconverter being configured, upon exposure to initiation energy, to generate light for emission into the medium, and (2) apply the initiation energy from an energy source including the first wavelength ?1 to the medium, wherein the emitted light directly or indirectly produces the change in the medium. A second method and system (1) place in a vicinity of the medium an agent receptive to microwave radiation or radiofrequency radiation, and (2) apply as an initiation energy the microwave radiation or radiofrequency radiation by which the agent directly or indirectly generates emitted light in the infrared, visible, or ultraviolet range to produce at least one of physical and biological changes in the medium.Type: ApplicationFiled: November 10, 2010Publication date: May 19, 2011Applicants: Immunolight, LLC, Duke UniversityInventors: Frederic A. Bourke, JR., Zakaryae Fathi, Ian Nicholas Stanton, Michael J. Therien, Paul Rath Stauffer, Paolo MacCarini, Katherine Sarah Hansen, Diane Renee Fels, Cory Robert Wyatt, Mark Wesley Dewhirst
-
Patent number: 7915254Abstract: The present invention relates to a method of photodynamic therapy and to a method of inducing a photocytoxic effect which comprises applying to an area to be treated an effective amount of a compound of formula in which R1, R2, R3 and R4 each independently is an optionally -substituted linear, branched or cyclic hydrocarbon group, or R1 and R2 together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7- membered ring or R3 and R4 together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7- membered ring; and where XP? is a counteranion and P is 1, 2 or 3; except for the compounds in which —NR1R2 and —NR3R4 are the same and are selected from —N(CH3)2 or —N(CH2CH3)2; and exposing the area to light to activate the compound.Type: GrantFiled: April 4, 2008Date of Patent: March 29, 2011Assignee: Photopharmica LimitedInventors: Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, David Ian Vernon
-
Patent number: 7906643Abstract: A methylene blue-curcumin hybrid useful in treating Alzheimer's Disease.Type: GrantFiled: February 1, 2010Date of Patent: March 15, 2011Assignee: Codman & Shurtleff, Inc.Inventor: Thomas M DiMauro
-
Patent number: 7893054Abstract: The present invention is directed to methods for the treatment or prophylaxis of a tauopathy comprising administering to a patient in need thereof a medicament comprising a phenothiazine.Type: GrantFiled: January 28, 2008Date of Patent: February 22, 2011Assignee: Wista Laboratories Ltd.Inventors: Claude Michel Wischik, David Horsley, Janet Elizabeth Rickard, Charles Robert Harrington
-
Publication number: 20110021510Abstract: This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methylhioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g.Type: ApplicationFiled: September 3, 2010Publication date: January 27, 2011Inventors: John Mervyn David STOREY, James Peter SINCLAIR, Colin MARSHALL, Han Wan TAN, Claude Michel WISCHIK
-
Patent number: 7855197Abstract: A phenothiazinium compound of Formula (I) wherein: A and B each independently is in which R? and R? each independently is a linear, branched or cyclic hydrocarbon group, or R? and R? together with the N atom to which they are attached form an optionally substituted 5-, 6- or 7-membered ring; and where XP? is a counteranion and P is 1, 2 or 3; except for the compounds in which A and B are both either —N(CH3)2 or —N(CH2CH3)2 for use in a treatment that requires removal, deactivation or killing of unwanted tissues or cells.Type: GrantFiled: June 18, 2008Date of Patent: December 21, 2010Assignee: Photopharmica LimitedInventors: Stanley Beames Brown, Cassandra Claire O'Grady, John Griffiths, Kirste Joanne Mellish, David Ian Vernon
-
Publication number: 20100310681Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: ApplicationFiled: June 3, 2010Publication date: December 9, 2010Applicant: MARQUETTE UNIVERSITYInventor: Mohammadhossein Behnam Ghasemzadeh
-
Publication number: 20100297247Abstract: The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:—an oil phase;—in said oil phase,—an aqueous droplet, or—a nanocapsule (NC) comprising:—an aqueous core, and—a polymeric shell or a shell composed of an amphiphilic substance; and—a surfactant. This composition is particularly useful for encapsulating hydrophilic and/or lipophilic substances.Type: ApplicationFiled: September 18, 2008Publication date: November 25, 2010Applicant: Institut National de la Sante et de la Recherche Medicale (Inserm)Inventors: Nicolas Anton, Patrick Saulnier, Jean-Pierre Benoit